Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Barcelona-Clinic Liver Cancer (BCLC) Staging Classification and Treatment Guidelines

    Determines progression of disease and proper treatment course for patients with HCC.
    When to Use
    Pearls/Pitfalls
    Why Use

    Patients diagnosed with hepatocellular carcinoma (HCC).

    • Classifies hepatocellular carcinoma into one of 4 stages (A-D, with 4 subgroups in stage A), with corresponding recommendations for treatment modalities.
    • Takes into account tumor features AND liver functional status, which are both known to affect prognosis.
    • Also accounts for presence of cancer-related symptoms.
    • Staging system of choice of the American Association for the Study of Liver Disease  (AASLD) and European Association for the Study of the Liver (EASL).
    • Links stage and prognosis to treatment strategy.
    • Alternative staging systems include TNM and Okuda classifications. TNM staging only accounts for tumor/node/metastasis characteristics (excludes liver function and patient functional status) and Okuda classification is less precise in stratifying earlier-stage tumors.
    • Child-Pugh and MELD scores also stratify HCC patients by prognostic factors.
    A
    B
    C

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Josep Llovet

    About the Creator

    Josep Llovet, MD, is a professor of medicine and founder and director of the Liver Cancer Program at Mount Sinai Hospital. He was the president, secretary and founder of the International Liver Cancer Association (ILCA) and Chairman of the European Clinical Practice Guidelines of management of liver cancer (EASL-EORTC). He is an active researcher investigating the pathogenesis and treatment of liver cancer.

    To view Dr. Josep Llovet's publications, visit PubMed

    Are you Dr. Josep Llovet? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
    MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.
    About the Creator
    Dr. Josep Llovet
    Are you Dr. Josep Llovet?